Neoadjuvant (Cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer

Obstetrics and Gynecology

Volumn 73, Issue 1, 1989, Pages 61-65

  Lawton, Frank G ^a   Redman, Charles W E ^a   Luesley, David M ^a   Chan, K K ^a   Blackledge, George ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; MITOXANTRONE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; HYSTERECTOMY; INTRAVENOUS DRUG ADMINISTRATION; OMENTUM; OVARY CANCER; PELVIS SURGERY; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FALLOPIAN TUBES; FEMALE; HUMAN; HYSTERECTOMY; MIDDLE AGE; MITOXANTRONE; OMENTUM; OVARIAN NEOPLASMS; OVARIECTOMY; REOPERATION;

EID: 0024496836     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol 1984;11:209–26.
2. Griffiths CT, Parker LM, Fuller AF Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235–40.
3. Wharton JT, Herson J. Surgery for common epithelial tumors of the ovary. Cancer 1981;48:582–9.
4. Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol 1985;20:190–5.
5. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1984;11:251–63.
6. Smith JP, Rutledge F. Chemotherapy in the treatment of cancer of the ovary. Am J Obstet Gynecol 1970;107:691–703.
7. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983;61:189–93.
8. Luesley DM, Lawton FG, Chan KK, Blackledge GR, Mould J. Second look laparotomy. In: Sharp F, Soutter WP, eds. Ovarian cancer—the way ahead. London: Royal College of Obstetricians and Gynaecologists, 1987:297–308.
9. Vogl SE, Seltzer V, Calanog A, et al. “Second effort” surgical resection for bulky ovarian cancer. Cancer 1984;54:2220–5.
10. Neijt JP, ten Bokkel Huininck WW, van der Burg MEL, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs Chap-5) in advanced ovarian carcinoma. Lancet 1984;ii:594–600.
11. Lawton FG, Blackledge G. Melphelan in epithelial ovarian cancer: Speed of clinical response as a predictor of activity. J Obstet Gynaecol (Bristol) 1986;7:135–8.
12. Lawton FG, Kelly KA, Sant Cassia L, Blackledge G. Speed of response to platinum based chemotherapy: Implications for the management of epithelial ovarian cancer. Eur J Cancer Clin Oncol 1987;23:1071–5.
13. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727–33.
14. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981;47:207–14.
15. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD. Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity. Obstet Gynecol 1986;67:783–8.
16. Piver MS, Baker T. The potential for optimal (<2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective study. Gynecol Oncol 1986;24:1–8.
17. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413–20.